GPC3-T2 CAR-T cell therapy (The Second Affiliated Hospital of Guangzhou Medical University)

N/A

Report date: 2022/10/25 17:50:50

Base Information

Drug NameGPC3-T2 CAR-T cell therapy (The Second Affiliated Hospital of Guangzhou Medical University)

Drug Alias NameN/A

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionGlypican-3 inhibitorsWnt signalling pathway inhibitors

TargetsGlypican-3

Therapy Area/IndicationsCarcinoma, Squamous CellCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesSecond Affiliated Hospital Of Guangzhou Medical University

China Registration ClassN/A

Develop Information

Active CompaniesSecond Affiliated Hospital Of Guangzhou Medical University

Inactive CompaniesN/A

Active IndicationsCarcinoma, Squamous CellCarcinoma, Hepatocellular

Inactive IndicationsN/A

Other Information

ATC CodeN/A